Invent Medic’s receives notice of allowance for patent in the USA
Invent Medic has received notice of allowance in the USA for a patent application in the USA for the company’s product Efemia bladder support. The patent will be valid until 2029.
The patent application (15/243834) covers a method for using the company’s product Efemia bladder support to reduce stress urinary incontinence (SUI). It will thus extend and strengthen the granted Efemia base patent in the USA. The base patent is also granted in Sweden and Europe.
”This decision will strengthen the patent protection for Efemia in the USA, which is important for our plans to launch Efemia in North America in the future. Invent Medic has implemented an ambitious and proactive global strategy for immaterial rights, and the USA is one of our most important markets. In addition to patents, this strategy includes design and brand protection so that we can achieve optimal scope and duration for the protection of our product portfolio,” says Invent Medic’s CEO Karin Bryder.
When issuing a notice of allowance, the patent office has the intention to grant the patent application following the final steps of the procedure, such as payment of the patent fee.
For more information, please contact
Karin Bryder, CEO
Telephone: +46 (0) 723 811 710
Email: info@inventmedic.com
This information is information that Invent Medic Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 29, 2018.
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.